CLCA4

CLCA4 is a secreted self-cleaving metalloprotease that modulates calcium-activated chloride currents and suppresses epithelial-to-mesenchymal transition across multiple epithelial tissues. The N-terminal cleavage product (N-CLCA4) is secreted and potentiates Ca2+-activated Cl- currents by engaging TMEM16B at the cell surface through its von Willebrand factor type A (VWA) domain and metal ion-dependent adhesion site (MIDAS) motif, with specificity for TMEM16B over TMEM16A (PMID:38825009). In epithelial cells of the breast, bladder, liver, colon, and esophagus, CLCA4 maintains the epithelial phenotype by suppressing PI3K/AKT signaling and EMT marker switching; its loss upregulates mesenchymal markers and promotes cell invasion (PMID:24386311, PMID:29190973, PMID:30312171). CLCA4 expression is post-transcriptionally repressed by miR-19a and miR-501-5p, which directly target its 3′-UTR to relieve its inhibition of PI3K/AKT-driven proliferation and invasion (PMID:35266369, PMID:32072405).

1. 2012 Low

   Before CLCA4's molecular mechanism was known, a genetic association study linked CLCA4 promoter variants to residual Ca2+-mediated chloride secretion in cystic fibrosis colonic tissue, providing the first human evidence that CLCA4 influences chloride conductance in vivo.

   Evidence Fine-mapping genetic association in a CF twin/sibling cohort (101 families) correlating promoter SNPs with Ca2+-mediated Cl- conductance endophenotype

   PMID:23073314

   Open questions at the time

   • Association only; no direct functional validation of CLCA4 variants on chloride channel activity
   • Causative variant and target channel were not identified
   • No in vitro reconstitution to distinguish CLCA4 effect from neighboring gene effects
2. 2013 Medium

   Establishing that CLCA4 is required to maintain epithelial identity, knockdown in mammary epithelial cells revealed that CLCA4 loss drives a full EMT program — the first demonstration of a non-ion-channel role for CLCA4.

   Evidence shRNA knockdown in immortalized mammary epithelial cells with qRT-PCR and protein analysis of E-cadherin, N-cadherin, vimentin, and fibronectin

   PMID:24386311

   Open questions at the time

   • Signaling pathway downstream of CLCA4 was not identified
   • Whether the EMT-suppressive role depends on CLCA4's protease or secreted activity was untested
   • Single cell-type study without rescue by re-expression
3. 2017 Medium

   Bidirectional gain- and loss-of-function experiments in bladder and later hepatocellular and colorectal cancer cells converged on PI3K/AKT as the signaling axis suppressed by CLCA4, mechanistically linking CLCA4 to inhibition of AKT phosphorylation and downstream EMT.

   Evidence Overexpression and shRNA knockdown in bladder cancer (2017), HCC (2018), CRC (2019), and esophageal carcinoma (2021) cell lines with Western blot for phospho-AKT/PI3K, Transwell invasion assays, and in vivo xenografts

   PMID:29190973 PMID:30312171 PMID:31164625 PMID:34194494

   Open questions at the time

   • Direct physical target linking CLCA4 to PI3K/AKT inhibition is unknown
   • Whether the secreted N-terminal fragment or membrane-tethered C-terminal fragment mediates EMT suppression is unresolved
   • No genetic knockout or CRISPR-based validation in non-cancer primary epithelial cells
4. 2020 Medium

   Identification of miR-501-5p and miR-19a as direct post-transcriptional repressors of CLCA4 revealed how CLCA4 is silenced in cancer, establishing upstream regulatory axes that derepress PI3K/AKT signaling.

   Evidence Luciferase reporter assays confirming direct 3′-UTR targeting plus co-transfection epistasis rescue experiments in HNSCC (miR-501-5p) and CRC (miR-19a) cells

   PMID:32072405 PMID:35266369

   Open questions at the time

   • Whether these miRNAs regulate CLCA4 in normal physiology or only in cancer contexts is unknown
   • No in vivo validation of the miRNA/CLCA4/PI3K axis
   • Other post-transcriptional regulators or promoter-level silencing mechanisms not explored
5. 2024 High

   Reconstitution of CLCA4's ion-channel-modulatory function demonstrated that the secreted N-terminal metalloprotease fragment potentiates TMEM16B-mediated Ca2+-activated Cl- currents through VWA/MIDAS domain-dependent engagement, resolving the molecular basis and target specificity of CLCA4's channel-regulatory activity.

   Evidence Electrophysiology in HEK293T cells co-expressing TMEM16A or TMEM16B with wild-type or VWA/MIDAS-mutant CLCA4, secretion assays, domain deletion constructs

   PMID:38825009

   Open questions at the time

   • Whether VWA/MIDAS-mediated TMEM16B engagement is related to the PI3K/AKT-suppressive EMT phenotype is unknown
   • Structural basis of CLCA4–TMEM16B interaction not determined
   • Physiological tissues where CLCA4–TMEM16B signaling operates in vivo not defined

• The mechanistic link between CLCA4's two established activities — TMEM16B-dependent chloride current potentiation and PI3K/AKT-mediated EMT suppression — remains unresolved, and it is unknown whether these reflect the same or independent pathways.
• No study has tested whether CLCA4's protease activity or secreted fragment is required for EMT suppression
• The direct molecular target linking CLCA4 to PI3K inhibition has not been identified
• In vivo physiological roles of CLCA4 in normal epithelial homeostasis have not been established with genetic models